Global Human Leukocyte Antigen (HLA) Typing for Transplant Market growth at a rate of 8.4% in the forecast period of 2022 to 2029

Global Human Leukocyte Antigen (HLA) Typing for Transplant Market growth at a rate of 8.4% in the forecast period of 2022 to 2029

• ·      Global Human Leukocyte Antigen (HLA) Typing for Transplant Market was valued at USD 778.19 million in 2021 and is expected to reach USD 1,483.61 million by 2029, registering a CAGR of 8.4% during the forecast period of 2022-2029. The "molecular assays" accounts for the largest technology segment in the human leukocyte antigen (HLA) typing for transplant market within the forecasted period owing to the benefits offered by molecular assays such as high procedural efficacy, low turnaround time, the study of multiple samples and real-time sample analysis. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

• ·      Human leukocyte antigen (HLA) typing determines if patients and donors are compatible for cord blood or bone marrow transplants. Human leukocyte antigens (HLA) are proteins found in our bodies. The human immune system uses these markers to determine which cells belong in your body and which cells are foreign.

• ·      The human leukocyte antigen (HLA) typing for transplant market is segmented on the basis of products and services, technology, transplant type, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

• ·      Reagents and Consumables
• ·      Instruments
• ·      Software and Services
• ·      On the basis of products and services, the human leukocyte antigen (HLA) typing for transplant market is segmented into reagents and consumables, instruments and software and services.

• ·      Molecular Assay Technologies
• ·      Non- Molecular Assay Technologies
• ·      On the basis of technology, the human leukocyte antigen (HLA) typing for transplant market is segmented into molecular assay technologies and non- molecular assay technologies. Molecular assay technologies are sub-segmented into PCR-based molecular assays and sequencing-based molecular assays. PCR-based molecular assays are further sub-segmented into Real-time PCR, sequence-specific primer-PCR, sequence-specific oligonucleotide-PCR and other PCR-based molecular assays. The sequencing-based molecular assays are further sub-segmented into sanger sequencing, next-generation sequencing and other sequencing-based molecular assays. The molecular assay technologies accounts for the largest share of the market because of benefits offered by molecular assays such as high procedural efficacy, low turnaround time, the study of multiple samples and real-time sample analysis.

• ·      Solid Organ Transplant
• ·      Hematopoietic Stem Cell Transplant
• ·      On the basis of transplant type, the human leukocyte antigen (HLA) typing for transplant market is segmented into solid organ transplant and hematopoietic stem cell transplant.

• ·      Diagnostic Applications
• ·      Research Application
• ·      On the basis of application, the human leukocyte antigen (HLA) typing for transplant market is segmented into diagnostic applications and research application.

• ·      Independent Reference Laboratories
• ·      Hospitals and Transplant Centres
• ·      Research Laboratories and Academic Institutes
• ·      On the basis of end user, the human leukocyte antigen (HLA) typing for transplant market is bifurcated into independent reference laboratories, hospitals and transplant centers, research laboratories and academic institutes.

• ·      The countries covered in the human leukocyte antigen (HLA) typing for transplant market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

• ·      The human leukocyte antigen (HLA) typing for transplant market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to human leukocyte antigen (HLA) typing for transplant market.

• ·      Thermo Fisher Scientific (U.S)
• ·      QIAGEN (Netherlands)
• ·      Illumina (US)
• ·      CareDx, (US)
• ·      Immucor, (U.S)
• ·      Bio-Rad Laboratories, Inc. (U.S)
• ·      F. Hoffman-La Roche Ltd. (Switzerland)
• ·      Hologic, Inc. (U.S)
• ·      Luminex Corporation (U.S)
• ·      Biofortuna (UK)
• ·      Bruker (US)
• ·      Abbott (US)
• ·      Takara Bio Inc.,(Japan)
• ·      Omixon Inc., (Hungary)
• ·      Siemens (Germany)
• ·      EKF Diagnostics (UK)
• ·  BD (US), Fujirebio, (Japan)   
• ·      TBG Diagnostics Limited (Australia)

• ·      INTRODUCTION
• ·      MARKET SEGMENTATION
• ·      EXECUTIVE SUMMARY
• ·      PREMIUM INSIGHTS
• ·      MARKET OVERVIEW
• ·      QUESTIONNAIRE